DEF: Anixa Biosciences Sets 2026 Annual Meeting Agenda

Anixa Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on March 10, 2026, to vote on director elections, executive compensation, and auditor ratification.

Summary

• The 2026 Annual Meeting of Stockholders for Anixa Biosciences, Inc. will be held virtually on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time.
• Stockholders will vote on the election of four director nominees: Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr., each for a one-year term expiring at the 2027 Annual Meeting.
• A non-binding, advisory vote will be held to approve the compensation of the named executive officers.
• Stockholders will also vote to ratify the appointment of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ending October 31, 2026.
• The Board of Directors unanimously recommends a vote FOR all director nominees, FOR the approval of named executive officer compensation, and FOR the ratification of the auditor appointment.

Sentiment

Score: 4

Explanation: The filing is a routine proxy statement with standard corporate governance proposals. While governance appears sound, the company's significant underperformance in Total Shareholder Return compared to its peer group and continued net losses indicate a challenging financial performance, tempering overall sentiment despite positive governance aspects.

Positives

• The Board of Directors unanimously recommends approval for all key proposals, including director elections, executive compensation, and auditor ratification, indicating internal alignment.
• The company maintains a robust corporate governance structure with a majority of independent directors on the Board and all key committees (Audit, Compensation, Nominating and Corporate Governance) composed exclusively of independent directors.
• Lewis H. Titterton, Jr. serves as the Lead Independent Director, providing an additional layer of independent oversight, especially given the CEO also holds the Chairman role.
• The company has adopted a formal code of ethics and an insider trading policy, promoting ethical conduct and compliance.
• The Compensation Committee explicitly states that equity awards are not granted in anticipation of, nor is the release of material nonpublic information timed based on, equity award grant dates, indicating sound compensation governance.

Negatives

• The company's cumulative Total Shareholder Return (TSR) significantly underperformed its peer group, the S&P Biotechnology Select Industry Index, for the periods ending October 31, 2023, 2024, and 2025.
• For the fiscal year ended October 31, 2025, the company's TSR was $73.75 compared to the peer group's $137.23 (based on a $100 investment on October 31, 2022).
• The company reported net losses of $11.0 million in fiscal year 2025, $12.7 million in 2024, and $9.9 million in 2023, indicating continued unprofitability as a pre-revenue entity.
• The Compensation Actually Paid (CAP) for the Principal Executive Officer (Dr. Amit Kumar) in 2023 was a negative $2,620,710, primarily due to changes in the fair value of outstanding and unvested option awards granted in prior years.

Risks

• As a pre-revenue biotechnology company, the company's financial performance and valuation are highly dependent on the successful development and commercialization of its technologies, which is inherently uncertain.
• The business model relies on conserving funds by collaborating with third parties to develop technologies, introducing dependency on external partners and potential risks associated with such collaborations.
• The value of executive and director equity awards, particularly stock options, is subject to market fluctuations and the company's stock price performance, which has underperformed its industry peer group.
• Stockholders who do not provide voting instructions to their brokers for non-routine matters (like director elections and executive compensation) may have their shares unvoted, potentially impacting the outcome of these proposals.

Future Outlook

Anixa Biosciences operates as a pre-revenue biotechnology company with a business model focused on conserving funds by collaborating with third parties to develop its technologies. The Compensation Committee's approach to executive compensation emphasizes the progress of technology development, operating expenses, and cash position, rather than a single financial performance measure. The company will continue to assess the inclusion of a Company-Selected Measure for compensation in the future.

Management Comments

• The Board unanimously recommends a vote FOR the election of each of the Director Nominees, FOR the approval on a non-binding, advisory basis, of the compensation of our named executive officers, and FOR the ratification of the appointment of the company's independent registered public accounting firm for the fiscal year ending October 31, 2026.
• Our goal for our executive compensation program is to attract, motivate and retain a talented team of executives who will provide leadership for our success, and thereby increase stockholder value.
• We believe that our executive compensation program satisfies this goal and is strongly aligned with the long-term interests of our stockholders.
• As a pre-revenue biotechnology company, with a business model that conserves funds by collaborating with third parties to develop its technologies, there is no single financial performance measure that is used when considering annual compensation for executives and directors.
• The Compensation Committee does not grant equity awards in anticipation of the release of material nonpublic information, nor does it time the release of material nonpublic information based on equity award grant dates.

Industry Context

Anixa Biosciences operates as a pre-revenue biotechnology company, a common characteristic in the early stages of drug development where significant R&D investment precedes commercialization. Its strategy of collaborating with third parties to develop technologies is a typical approach for smaller biotech firms to manage capital expenditure and leverage external expertise. The comparison to the S&P Biotechnology Select Industry Index highlights the broader market performance for similar companies, against which Anixa has underperformed.

Comparison to Industry Standards

• The company's cumulative Total Shareholder Return (TSR) of $73.75 for 2025 (from an initial $100 investment on October 31, 2022) significantly underperformed the S&P Biotechnology Select Industry Index, which recorded a TSR of $137.23 over the same period.
• The company's consistent net losses ($11.0 million in 2025, $12.7 million in 2024, and $9.9 million in 2023) are typical for a pre-revenue biotechnology company focused on research and development, but the underperformance in TSR relative to the industry index suggests that the market has not rewarded its progress as favorably as the broader biotech sector.
• The compensation structure, which does not rely on a single financial performance measure due to the pre-revenue stage, aligns with practices in early-stage biotech where milestones and R&D progress are often prioritized over immediate profitability, rather than traditional revenue or profit metrics.

Corporate Governance

Related Party Transactions

• Aside from compensation arrangements with executive officers, no other transactions entered into by the company with related persons were disclosed.

Stakeholder Impact

• Shareholders will directly impact corporate governance by voting on director elections, executive compensation, and the appointment of the independent auditor.
• Executive officers and directors are subject to shareholder advisory votes on their compensation, and their continued roles are dependent on re-election.
• The company's strategic focus on technology development through collaborations, as a pre-revenue entity, impacts employees by shaping the company's long-term growth trajectory and operational priorities.
• The independent auditor, Haskell & White LLP, will have their appointment for fiscal year 2026 ratified by shareholders, affirming their role in ensuring financial transparency.

Next Steps

• Stockholders are requested to vote on the election of directors, advisory approval of executive compensation, and ratification of the independent auditor at the virtual Annual Meeting on March 10, 2026.
• The company will announce voting results at the Virtual Meeting and file a Current Report on Form 8-K.
• The Compensation Committee will continue to assess the decision regarding the inclusion of a Company-Selected Measure for executive compensation on a forward-looking basis.

Key Dates

Recommendation

The filing is a routine proxy statement outlining standard corporate governance matters for the upcoming annual meeting. While the company maintains a structured board and compensation practices, its Total Shareholder Return has significantly underperformed the S&P Biotechnology Select Industry Index over the past three fiscal years, and it continues to report net losses. As a pre-revenue biotechnology company, its valuation is heavily tied to pipeline progress and future collaborations, which are not detailed in this filing. The current information does not present a compelling reason for a 'buy' due to underperformance, nor a 'sell' as it's a standard governance update without new negative operational news. Therefore, a 'hold' recommendation is appropriate, awaiting further operational updates or financial results that could alter the investment thesis.

Keywords

Anixa Biosciences, ANIX, Proxy Statement, DEF 14A, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Biotechnology, Shareholder Vote, SEC Filing, Stock Options, Total Shareholder Return